Vis enkel innførsel

dc.contributor.authorOttestad, William Arne
dc.contributor.authorRognes, Ingrid Nygren
dc.contributor.authorPischke, Søren
dc.contributor.authorMollnes, Tom Eirik
dc.contributor.authorAndersson, Ulf
dc.contributor.authorEken, Torsten
dc.date.accessioned2020-02-26T14:01:37Z
dc.date.available2020-02-26T14:01:37Z
dc.date.issued2019-08
dc.description.abstract<i>Objective</i>: The causal role of the prototype alarmin high mobility group box 1 protein (HMGB1) in systemic inflammation and remote organ injury after trauma and shock is established in animal models but not in humans. Our aim was therefore to determine HMGB1 concentration kinetics with high time resolution during the first hours after trauma in individual patients, and investigate the association with outcome.<p> <p><i>Design</i>: Prospective single-center observational study.<p> <p><i>Setting</i>: University hospital Level I trauma center.<p> <p><i>Patients</i>: Convenience recruitment of 136 trauma patients.<p> <p><i>Interventions</i>: None.<p> <p><i>Measurements and Main Results</i>: Total plasma HMGB1 levels were analyzed with ELISA in repeated samples. Relationships between predefined predictor variables and outcome were examined in multivariable linear regression models. Ventilator-free days was used as primary outcome measure. Two distinct HMGB1 release phases were identified. An initial exponential decay phase with a half-life of 26 min was not correlated with outcome. In contrast, a second HMGB1 wave peaking 3–6 hours after trauma in the most severely injured and physiologically deranged patients was strongly correlated with outcome.<p> <p><i>Conclusions</i>: HMGB1 was released in two consecutive phases. Only the second HMGB1 wave was a significant predictor of outcome. Patients with a high HMGB1 concentration between 3 and 6 hours after trauma might benefit from HMGB1-specific antagonist therapy.en_US
dc.identifier.citationOttestad W, Rognes IN, Pischke SE, Mollnes TE, Andersson U, Eken T. Biphasic release of the alarmin high mobility group box 1 protein early after trauma predicts poor clinical outcome. Critical Care Medicine. 2019;47(8):e614-e622en_US
dc.identifier.cristinIDFRIDAID 1722898
dc.identifier.doi10.1097/CCM.0000000000003800
dc.identifier.issn0090-3493
dc.identifier.issn1530-0293
dc.identifier.urihttps://hdl.handle.net/10037/17517
dc.language.isoengen_US
dc.publisherLippincott, Williams & Wilkinsen_US
dc.relation.journalCritical Care Medicine
dc.relation.projectIDinfo:eu-repo/grantAgreement/EU/FP7-HEALTH/602699/?/Disarming the intravascular innate immune response to improve treatment modalities for chronic kidney disease/DIREKT/en_US
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medical disciplines: 700en_US
dc.subjectVDP::Medisinske Fag: 700en_US
dc.titleBiphasic release of the alarmin high mobility group box 1 protein early after trauma predicts poor clinical outcomeen_US
dc.type.versionacceptedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel